Eligible RCTs compared angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium channel blockers (CCBs), or diuretics with another drug class or placebo and reported stroke incidence. The gene discussed is ACE; the disease is stroke disorder.